Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 10, 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes and Transactions
On June 9, 2016, the following Directors and PDMRs acquired GSK Ordinary Shares through the GSK ShareReward Plan:
- Transaction Price: 1,441.43 pence per Ordinary Share.
- Participants: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Acquisition Structure: Each participant acquired 9 shares under the personal contribution element and 9 shares under the matching element (GSK contribution).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares acquired by each listed Director/PDMR (18 shares per individual).
- Confirm the transaction price of 1,441.43 pence per share against market data for June 9, 2016.
- Review the specific terms of the GSK ShareReward Plan to understand the vesting or holding requirements for the acquired shares.